Abstract:Abstract Background Despite the advance in neoadjuvant chemothepray/chemoradiotherapy and favourable outcomes of surgical management in supraclavicular lymph node (SCLN) involvement reported in recent studies, the latest AJCC/UICC TMN classification still regards SCLN metastasis as extra-regional i.e Stage IVB (M1) disease. The role of SCLN dissection and surgical management remain controversial. At National University Hospital of the present study, bilateral supraclavicular lymphadenectomy is routinely performed for resectable thoracic ESCC. The aim of this retrospective cohort study is to investigate the long-term outcome of surgical management in pathological SCLN metastasis and its survival benefit comparing to Stage IIB-IVA diseases. Methods Patients with ESCC who underwent esophagectomy and 3-field lymphadenectomy with curative intent between January 2013 and January 2023 at the single centre were included; cases of salvage esophagectomy post-definitive concurrent chemoradiotherapy, palliative resections, and concurrent head and neck cancers were excluded. Neoadjuvant treatments were considered in cases staged clinically as T2 and/or N1 or greater. Pathological status of lymph nodes was recorded according to JES classification. Demographics and prognostic factors were examined using univariant analysis of overall survival (OS). Patients with SCLN metastases and other LN involvements were compared and OS were analysed using Kaplan-Meier method. Results 544 patients were included. 183 had one or more pathological LN metastasis (pN1:126, pN2 46, and PN3: 11) in which 55 patients had SCLN metastasis. Patients with LN metastasis had poorer prognosis than those without (pN0) with a Hazard Ratio (HR) of 2.68 (95% CI, 1.12-3.40, p<0.01); similar pattern was seen in patients with SCLN metastasis (HR 2.28, p<0.01). The 3-year and 5-year OS of patients with SCLN metastasis was 18.5% and 11.6% respectively whereas those of other LN metastasis was 21.4% and 15.8%; the difference between the groups was not statistically significant (p=0.525) (graph 1). Conclusion Lymph node status (pN) is a well-recognised prognostic factor as reaffirmed, however, within the pN positive cohort, long-term survival of patients with SCLN metastasis, considered as stage IVB (M1), was comparable (p<0.05) to those with other LN metastases. This supports the survival benefit of surgical resection with neoadjuvant therapy in SCLN metastases as following nodal disease treatment algorithm; further evaluation including systemic therapy and lymph node sub-group analysis is being conducted. Whilst randomised controlled trials such as Japanese JCOG2013 provides level I evidence, the present study provides complementary real-world experience for SCLN dissection.

The clinical screening indication of N3 lymph node biopsy performed at mediastinoscopy in NSCLC

Evaluation of Scalene Lymph Node or Contralateral Mediastinum Biopsy During Mediastinoscopy for Non-Small Cell Lung Cancer

Distribution and prognosis of mediastinal lymph node metastases of nonsmall cell lung cancer.

Evaluation of Lymph Node Metastasis in the Contralateral Mediastinum or Scalene Through Mediastinoscopy and Para-Mediastinal Small Incision in Potentially Operable Non-Small Cell Lung Cancer

Clinical Value of Cervical Mediastinoscopy in Non-small Cell Lung Cancer of Stage I

555. SUPRACLAVICULAR NODE INVOLVEMENT, A NODAL OR METASTATIC DISEASE? - A 10-YEAR EXPERIENCE IN ESOPHAGEAL CARCINOMA AT A TERTIARY REFERRAL CENTRE

[Risk Factor Analysis of Mediastinal Lymph Node Metastasis in Non-Small Cell Lung Cancer Patients and the Strategy of Mediastinoscopy Prior to Surgery].

Evaluation of preoperative mediastinoscopy on of mediastinal lymph nodes metastases in patients with nonsmall cell lung cancer after undergoing mediastinoscopy.

Predictive Risk Factors for Lymph Node Metastasis in Patients with Small Size Non-Small Cell Lung Cancer.

Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis.

Risk Analyses of N2 Lymph-Node Metastases in Patients with T1 Non-Small Cell Lung Cancer: a Multi-Center Real-World Observational Study in China

Value of Mediastinoscopy in Preoperative Staging of Non-Small Cell Lung Cancer--based on Survival Analysis

Prognostic role of station 3A mediastinal nodes for non-small-cell lung cancers.

The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer

The value of mediastinoscopy in the staging of lung cancer with clinical N2 disease

Mediastinal lymphadenectomy fulfilling NCCN criteria may improve the outcome of clinical N0-1 and pathological N2 non-small cell lung cancer.

Number of involved nodal stations: a better lymph node classification for clinical stage IA lung adenocarcinoma

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration and Cervical Mediastinoscopy for Mediastinal Staging of Non-Small Cell Lung Cancer: a Retrospective Comparison Study.

Clinical application of mediastinoscopy in the diagnosis of thoracic disease

Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A prospective, multicenter, clinical trial